Catalyst Wire Dossier Catalyst Wire Dossier
EMA approval · 2022-06-24

EMA Authorised: Desloratadine ratiopharm (desloratadine) — Ratiopharm GmbH

View source ↗

Summary

Authorised desloratadine product Desloratadine ratiopharm by Ratiopharm GmbH for allergic rhinitis and urticaria indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Desloratadine ratiopharm (desloratadine)

Snippet

Status: Authorised. Therapeutic area: Rhinitis, Allergic, Perennial;Urticaria;Rhinitis, Allergic, Seasonal. MAH: Ratiopharm GmbH. Decision date: 22/06/2022